摘要
74岁男性患者因确诊Ⅲa期支气管肺鳞癌,在上海交通大学医学院附属瑞金医院接受白蛋白结合型紫杉醇及卡铂化疗联合帕博利珠单抗新辅助治疗。1周后患者出现免疫治疗相关4级皮肤毒性反应,予以激素治疗后Stevens-Johnson综合征和中毒性表皮坏死松解症好转。免疫相关不良反应发生与较好的免疫治疗疗效相关,缩瘤效果显著。本例患者仅使用1个周期PD-1抑制剂治疗后术后病理证实肺癌完全缓解。
A 74-year-old man with stageⅢsquamous lung cancer received chemotherapy(albumin-bound paclitaxel and Carboplatin),combined with Pembrolizumab as neo-adjuvant therapy in Ruijin Hospital affiliated to Shanghai Jiao-tong University Medical College.Immune-related adverse reactions grade 4 cutaneous toxicity occurred 1 week later,and was stimulated Stevens-Johnson syndrome and toxic epidermal Necrolysis improved after treatment.The occurrence of immune-related adverse reactions was associated with significant tumor shrink.Postoperative pathology confirmed complete remission of lung cancer only after one cycle of PD-1 inhibitor.
作者
张琼
王晓斐
Zhang Qiong;Wang Xiaofei(Department of Pulmonary and Critical Care Medicine,People’s Hospital of Wuwei,Wuwei 733000,China;Institute of Respiratory Diseases,Shanghai Jiao Tong University School of Medicine,Shanghai Key Laboratory of Emergency Prevention,Diagnosis and Treatment of Respiratory Infectious Diseases,Department of Pulmonary and Critical Care Medicine,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
出处
《中华转移性肿瘤杂志》
2022年第4期347-351,共5页
Chinese Journal of Metastatic Cancer
基金
国家自然科学基金(81702250)
吴阶平医学基金会临床科研专项资金基金(320.6750.19088-97)
关键词
肺鳞癌/免疫疗法
免疫相关不良反应
病理完全缓解
Squamous lung cancer/immunotherapy
Immune-related adverse event
Pathological complete remission
